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Abstract
The pharmacological management of COVID-19 has evolved significantly and various
immunomodulatory agents have been repurposed. However, the clinical efficacy has been
variable and a search for cure for COVID-19 continues. A retrospective cohort study was
conducted on 916 patients hospitalized with polymerase chain reaction (PCR)-confirmed
COVID-19 between February 2020 and October 2020 at a tertiary care academic medical
center in Karachi, Pakistan. The median age was 57 years (interquartile range (IQR) 46–66
years). The most common medications administered were Methylprednisolone (65.83%),
Azithromycin (50.66%), and Dexamethasone (46.6%). Majority of the patients (70%) had at
least two or more medications used in combination and the most frequent combination was
methylprednisolone with azithromycin. Overall in-hospital mortality was 13.65% of patients.
Mortality was found to be independently associated with age greater than or equal to 60
years (OR = 4.98; 95%CI: 2.78–8.91), critical illness on admission (OR = 13.75; 95%CI:
7.27–25.99), use of hydrocortisone (OR = 12.56; 95%CI: 6.93–22.7), Ferritin> = 1500(OR =
2.07; 95%CI: 1.18–3.62), Creatinine(OR = 2.33; 95%CI: 1.31–4.14) and D-Dimer> = 1.5
(OR = 2.27; 95%CI: 1.26–4.07). None of the medications whether used as monotherapy or
in combination were found to have a mortality benefit. Our study highlights the desperate
need for an effective drug for the management of critical COVID-19 which necessitates
usage of multiple drug combinations in patients particularly Azithromycin which has long
term implications for antibiotic resistance particularly in low-middle income countries.

Introduction
As of August 2021; Corona Virus Disease 2019 (COVID-19) has caused more than 4 million
deaths worldwide [1]. The treatment strategy for COVID-19 involves providing general supportive care, respiratory support, symptomatic treatment, nutritional support, and psychological intervention [2]. Various pharmacological agents have reduced disease severity and
mortality [3].
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Clinical outcomes of immunomodulatory therapies in the management of COVID-19

Numerous observational studies and clinical trials have evaluated the effectiveness of several drug classes, including antivirals, anti-inflammatory agents, immunomodulators, corticosteroids, novel therapeutic agents, and novel small molecule inhibitors or Janus kinase (JAK)
inhibitors [4,5]. Therapies targeting viral replication, such as remdesivir, have shown to be
effective in shortening the time to recovery in patients suffering from COVID-19 [6]. The
anti-interleukin-6 (IL-6) receptor antibody tocilizumab reportedly reduced the likelihood of
mechanical ventilation and death [7–9]. The use of glucocorticoids in hospitalized patients
with COVID-19 has been associated with improved clinical outcomes and decreased mortality
[10,11]. In addition, the efficacy of other pharmacological agents used in the treatment of
COVID-19 has been studied notably azithromycin [12,13] and hydroxychloroquine [14,15].
However, the list is exhaustive as the search for cure continues. Of all the experimental agents
used for COVID 19, the most substantial evidence has emerged for IL-6 inhibition with Tocilizumab and Sarilumab [16]. Both drugs have World health organization (WHO) endorsement
for management of Critical COVID as well as food and drug administration (FDA) approval
for Tocilizumab [17].
The pharmacological management of COVID-19 has evolved significantly, leading to novel
therapeutics, including monoclonal antibodies and Janus-kinase inhibitors. However, lowand middle-income countries (LMICs) like Pakistan face significant challenges in managing
COVID-19, given scarce drug procurement resources for inpatient care [18]. While considerable evidence has evolved in favor of, and various immunomodulatory agents have been repurposed, evidence on their clinical efficacy remains to be established [19]. A concerted effort is
needed to evaluate the potential of these agents. Therefore, we aim to describe the patterns of
pharmacotherapy for COVID-19, emphasizing the number of drug combinations used in a
given time in patients with severe COVID-19.

Materials and methods
We conducted a retrospective cohort study in COVID-19 patients admitted from February
2020 to October 2020. Ethical approval was obtained before the commencement of the study
from the Aga Khan University ethics review committee (AKU ERC Reference number: 20204939-11055). All adult patients greater than or equal to 18 years of age who had tested positive
for SARS-CoV-2 by nasopharyngeal reverse transcriptase polymerase chain reaction
(RT-PCR) were included. Cytokine storm (CS) or hyperinflammation was defined as serum
C-reactive protein (CRP) �100 mg/L, ferritin �900 ng/mL, or both. Non-severe COVID-19
was described as having symptoms of fever, cough, or other symptoms with radiographic evidence of pneumonia but no hypoxia or evidence of CS. Severe disease was defined as having
respiratory distress, respiratory rate >30 breaths/min on rest, Oxygen saturations of <93%,
and Partial Pressure of Oxygen to Fraction of Inspired Oxygen Ration (PaO2/Fio2)
<300mmHg. The acute disease was defined as respiratory failure requiring mechanical ventilation and shock with or without multiorgan dysfunction requiring Intensive Care Unit (ICU)
monitoring. Data was collected on a structured proforma from the hospital information management system (HIMS) Department at Aga Khan University hospital (AKUH) on patients
admitted with COVID-19. Outcome variables included in-hospital mortality and length of
stay.

Statistical analysis
Median with interquartile range (IQR) was computed for age and length of hospital stay
(LOS), and frequencies (percentage) were calculated for variables such as gender and outcomes. Continuous variables were assessed after appropriate transformation into categorical
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variables depending on clinical relevance. χ2 test of independence was performed for comparison of results. Univariable and multivariable logistic regression analysis was performed to
determine risk factors associated with in-hospital mortality. Adjusted odds ratios with Confidence Intervals were reported. We included interaction terms to identify any interaction
between different therapeutic options. STATA Version 12.1 was used for data analysis.
Furthermore, the dataset included all date-wise records for all drugs prescribed and lab
tests conducted on all hospitalized COVID-19 patients at AKUH between February 2020 and
October 2020. Pattern recognition was used to get the primary filtered name for each drug.
The filtered primary terms were assigned to one or none of the set categories: Hydrocortisone;
Remdesivir; Hydroxychloroquine; Tocilizumab; Dexamethasone; Azithromycin; and Methylprednisolone. The selected combination of drugs was then presented using an upset diagram.
Time-based graphs were created to study the impact of medications on selected labs: Ferritin;
C—reactive protein; lactate dehydrogenase (LDH) and D-Dimer. To make the chart of each
drug, relative lab results were calculated, keeping the first day of drug prescription as the reference day. Results 7-day before and 7-days after each drug administration were considered. The
patients were pooled into two groups based on COVID-19 severity, into severe and non-severe
patients. Severe patients were identified based on either Ferritin lab results greater than 1500
or C-reactive protein greater than 150 anytime during their stay. Stratified line graphs were
created using the median results of each day for each patient group. To mitigate the impact of
the non-daily test, a geom_smooth function was used on the line graphs. All analysis was done
in R and Stata ver 12.1.

Results
Patient demographics
We collected data from 916 patients hospitalized with PCR-confirmed COVID-19 between
February 2020 and October 2020. The median age of the included patients was 57 years (IQR
46–66 years). Most patients (68.88%) were over the age of 50 years and majority were male
(66.48%). Co-morbid data was available for n = 700 patients. The most frequent co-morbids
were Diabetes mellitus (DM) in 44.5%, hypertension in 44% and ischemic heart disease (IHD)
in 12.2%. The most common medications administered were Methylprednisolone (65.83%),
Azithromycin (50.66%), and Dexamethasone (46.6%) (Fig 1). In-hospital mortality was seen in
13.65% of patients, whereas 78.82% were alive at discharge, and 7.53% left the hospital against
medical advice.
A decline in median inflammatory parameters between Day 1 and Day 3 of admission and
treatment initiation was observed for C-reactive protein (71.92 mg/L (IQR 29.85–150.31) to
26.87 mg/L (IQR 12.94–54.76)), Procalcitonin (0.16 ng/ml (IQR 0.08–0.50) to 0.12 ng/ml (IQR
0.06–0.39)) and percentage of lymphocytes (11.3(IQR 6.6–18.6) to 9.8 (IQR 6.1–15.1)). As
opposed to this; a rise in median values of D-dimer(1.1 mcg/mL (IQR 0.6–2.9) to 1.2 mcg/mL
(IQR 0.6–3.3), ferritin (787.45 ng/ml(IQR 379.85–1368.25) to 909.10 ng/ml (IQR 524.90–
1382.90), LDH (435 I.U/L (IQR 336–583) to 438 I.U/L (IQR 340–572) and Creatinine (0.9 mg/
dL (IQR 0.7–1.2) to 1.0 mg/dL (IQR 0.7–1.4) was observed between Day 1 and Day 3 of admission despite initiation of medication and this difference was more marked for those with severe
COVID-19 (Fig 2).

Logistic regression analyses
On univariate analysis; a CRP > = 100 (P<0.001), Ferritin> = 1500 (P<0.001), D-Dimer >1.5
(P<0.001) and LDH> = 250 (P = 0.023) held a statistically significant association with death
(Table 1). Among co-morbid conditions, ischemic heart disease was significantly associated
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Fig 1. Combinations of drugs used in management of COVID-19. In this Upset graph, each row represents a drug.
Each column represents a combination of drugs. A filled dot indicates that drug is included in the column
combination.
https://doi.org/10.1371/journal.pone.0262608.g001

with mortality (P = 0.038). Among medications, administration of Hydrocortisone (P<0.001),
Hydroxychloroquine (P = 0.013), Methylprednisolone (P = 0.008) and Tocilizumab
(P = 0.021) were associated with ICU admission and death. Moreover, at least 4 or more drugs
were being used in combination in patients who died (<0.001). However in multivariate logistic regression analysis, mortality was found to be independently associated with age greater
than or equal to 60 years (aOR = 4.98; 95%CI: 2.78–8.91), critical illness on admission
(aOR = 13.75; 95%CI: 7.27–25.99), use of hydrocortisone (aOR = 12.56; 95%CI: 6.93–22.7),
Ferritin> = 1500(aOR = 2.07; 95%CI: 1.18–3.62), Creatinine(aOR = 2.33; 95%CI: 1.31–4.14)
and D-Dimer> = 1.5 (aOR = 2.27; 95%CI: 1.26–4.07) (Table 2). None of the medications
whether used as monotherapy or in combination were found to have a mortality benefit and
none of the co-morbids were found to be independently associated with death.

Discussion
The greatest concern in management of critical COVID-19 patients is survival. Our study
sought to investigate the patterns in pharmacotherapy and the factors associated with in-hospital mortality. Notable findings included an increased risk of death with advanced age, critical
illness and acute kidney injury based on serum creatinine greater than 1.5 mg/dl as well as biomarkers such as Ferritin and D-Dimer. Moreover, we found a trend towards greater number
of medications used in combination in critically ill patients.
Scientific evidence on pharmacological management of COVID-19 continues to evolve and
is in a state of flux [20]. Following the pandemic, hydroxychloroquine utilization increased
rapidly due to its immunomodulatory properties, but it declined sharply after May 2020 due to
safety concerns and a lack of efficacy data [21]. In contrast, the use of dexamethasone and corticosteroids progressively increased during 2020 based on findings from the randomized evaluation of COVID-19 therapy (RECOVERY Trial) [10,22,23]. Corticosteroid therapy is used in
COVID 19 to mitigate the inflammatory response in the lungs [24]. Methylprednisolone was
the most commonly administered medication in COVID-19 patients in our study cohort
although it did not improve survival. A randomized controlled trial (RCT) involving severe
hospitalized COVID-19 patients receiving Methylprednisolone versus standard of care showed
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Fig 2. Median laboratory values of inflmmatory markers in relation to administration of drug stratified by
severity of COVID-19. The graphs show the median lab values of patient in Severe and Non-severe categories against
days relative to the day of the administration of the drug. Each graph has been smoothed using a regression function to
mitigate for sparingly conducted lab tests.
https://doi.org/10.1371/journal.pone.0262608.g002

that patients in the methylprednisolone group had significantly increased survival times and
higher rates of clinical improvement compared with patients in the standard care group [25].
IL-6 inhibition with Tocilizumab and Sarilumab has changed the treatment paradigm for
severe and critically ill patients with COVID 19. An insight into the pathophysiology of cytokine storms led to a corresponding biochemical evaluation of IL-6, LDH, Ferritin, C reactive
protein, D-Dimer in susceptible patients [26]. Most of the patients who were managed in special and intensive care units had significant elevations of cytokine release syndrome (CRS) biomarkers. These patients received Tocilizumab as salvage therapy, although it turned out that
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Table 1. Comparison of COVID-19 patients who died and who survived.
Variables

Died (n = 125)

Alive (n = 722)

p-value

65 (56–75)

55 (44–65)

<0.001

3 (2.4)

35 (4.9)

30–49

10 (8.0)

219 (30.3)

50–69

60 (48.0)

357 (49.5)

> = 70

52 (41.6)

111 (15.4)

Male

87 (69.6)

471 (65.2)

Female

31 (30.4)

251 (34.7)

68 (58.6)

57 (7.12)

<0.001
<0.001

Median Age (IQR) years
Age Range n (%)
18–29

<0.001

Gender n (%)

Critical illness

0.342

Laboratory parameters
CRP <100 (Ref)

54 (43.2)

438 (60.7)

CRP > = 100

71 (56.8)

284 (39.3)

Ferritin <1500 (Ref)

72 (57.6)

546 (75.6)

Ferritin> = 100

53 (42.4)

176 (24.4)

D-Dimer <1.5 (Ref)

30 (24.0)

412 (57.1)

D-Dimer >1.5

95 (76.0)

310 (42.9)

LDH <250 (Ref)

<0.001
<0.001

3 (2.4)

57 (7.9)

122 (97.6)

665 (92.1)

Azithromycin

60 (48.0)

363 (50.2)

Dexamethasone

53 (42.4)

337 (46.7)

0.376

Hydrocortisone

73 (58.4)

38 (5.3)

<0.001

Hydroxychloroquine

33 (26.4)

123 (17.0)

0.013

Methylprednisolone

96 (76.8)

467 (64.6)

0.008

Remdesivir

17 (13.6)

91 (12.6)

0.758

Tocilizumab

26 (20.8)

94 (13.0)

0.021

<4 (Ref)

88 (11.9)

653 (88.1)

>=4

37 (34.9)

69 (65.1)

LDH> = 250

0.023

Medications n (%)

Number of drug combinations n (%)

0.638

<0.001

Abbreviations: IQR: Interquartile range; CRP: C-reactive protein; LDH: Lactate dehydrogenase.
https://doi.org/10.1371/journal.pone.0262608.t001

many patients still had poor outcomes due to the severity of the disease. Moreover, raised Ddimer level, Ferritin, and C-reactive protein (CRP) levels were also associated with mortality.
In a case-control study, D-dimer levels correlated with disease severity and were a reliable
prognostic marker for in-hospital mortality in patients admitted for COVID-19 [27]. In
another study, the hospitalization-wide median CRP was significantly higher amongst the
patients who died than those who survived [28].
The in-hospital mortality for our patient population was 13.65%, which was similar to the
global trends of in-hospital mortality among hospitalized COVID-19 patients [29]. Multivariate logistic regression results showed that age and critical illness in our patient cohort were
independently associated with mortality. This finding is similar to a retrospective cohort study
of hospitalized COVID-19 patients treated in 592 hospitals in the United States which found
that in-hospital mortality rates were more significant in older patients [30]. A review by Ejaz
et al. describes that patients with co-morbid conditions were at higher risk of severe illness and
adverse outcomes [31]. In our study we did not find co-morbid conditons such as DM,

PLOS ONE | https://doi.org/10.1371/journal.pone.0262608 January 27, 2022

6 / 10

PLOS ONE

Clinical outcomes of immunomodulatory therapies in the management of COVID-19

Table 2. Multivariable logistic regression model for factors associated with in-hospital mortality.
Variable

Categories

OR

Age

< 60 years (Ref)

1

> = 60 years

4.98

Critical illness

Absent (Ref)

1

Present

13.75

Use of Hydrocortisone

Absent (Ref)

1

Present

12.56

Creatinine

< 1.5 (Ref)

1

> = 1.5

2.33

Ferritin

< 1500(Ref)

1

> = 1500

2.07

D-Dimer

< 1.5 (Ref)

1

> = 1.5

2.27

95% CI

p-value

2.78–8.91

<0.001

7.27–25.99

< 0.001

6.93–22.7

<0.001

1.31–4.14

0.004

1.18–3.62

0.011

1.26–4.07

0.006

https://doi.org/10.1371/journal.pone.0262608.t002

hypertension and IHD to be associated with poor prognosis although there was a trend
towards higher mortality in IHD patients in univariate analysis. This is similar to large study
from Bergamo, Italy by Novelli et al. in which co-morbids were not found to be significantly
associated with mortality [32].
Patterns of pharmacotherapy, specifically the drug regimens and combinations received by
hospitalized patients during their stay, were studied by presenting a selected combination of
drugs using an upset diagram. The most frequently used drug combinations were Methylprednisolone and Azithromycin followed by methylprednisolone and Tocilizumab. Fewer studies
have shown data on use of combination treatment in COVID-19. In one retrospective cohort
study, the top three treatment combinations were ‘Anticoagulation Only,’ ‘Anticoagulation
and Hydroxychloroquine’ and ‘Anticoagulation and Corticosteroids’ [33].
More than half of the patients in our cohort who died developed critical illness (58.6%).
The patients who survived received < four-drug combinations. On the other hand, the majority of patients who died received > = four-drug regimen. These trends are consistent with the
findings from a study on pharmacological treatment patterns by COVID-19 severity. It
showed that patients with greater disease severity (intubated, requiring mechanical ventilation)
were 3.53 times more likely to receive a medication to treat COVID-19 [34].
Thus, we report one of the most extensive studies on the inpatient clinical management of
COVID-19 from Pakistan, a lower-middle-income country in South Asia. We hope that it will
inform best practices for other developing countries and drive a search for more potent and
effective pharmacotherapeutics, and for the scientific community to include patients from
developing countries in their ongoing clinical trials. The main limitations of this study are that
our findings are based on results from a single health care facility and we have used retrospective design which carries risk of missing data. Therefore, larger multi-center studies are
required to validate and strengthen these findings further.

Conclusion
Our study highlights the desperate need for an effective drug for the management of critical
COVID-19 which necessitates usage of multiple drug combinations in patients particularly
Azithromycin which has long term implications for antibiotic resistance particularly in lowmiddle income countries.
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